Mitomycin Instillation for Low-Grade Bladder Cancer: Results
Home Instillation of Mitomycin Shows Promise for Bladder Cancer Treatment
Table of Contents
A recent Phase 3b study has demonstrated the feasibility and patient preference for home-based administration of mitomycin for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The findings, published in Uro oncol, suggest a notable shift towards more patient-centric and accessible cancer care models.
Key Findings and Safety Profile
The study focused on the home instillation of mitomycin utilizing RTGel® technology, a sustained-release hydrogel formulation designed to prolong drug exposure to bladder tissue. The treatment regimen involved once-weekly instillations over a six-week period. While the initial dose was administered in a clinical setting,the subsequent five doses were delivered at the patient’s home by a trained professional.
The most commonly reported adverse events were mild-to-moderate urinary symptoms, a profile consistent with previous administrations. Importantly, no new safety concerns were identified with the home-based administration approach, underscoring it’s safety. The high completion rate of the treatment regimen further highlights the feasibility and patient adherence to this delivery model in a home environment.
Patient Preference and Convenience
Patient feedback,gathered through feasibility questionnaires,strongly supported the utility of the home-based approach. Out of the six patients who completed the full course of treatment, five indicated they would recommend this method. This strong preference points to the significant value patients place on the convenience and comfort of receiving care in their own homes, a crucial factor for long-term adherence and overall quality of life in managing chronic conditions like NMIBC.
Implications for Bladder Cancer Care
The ability to administer mitomycin at home has far-reaching implications for bladder cancer management. It has the potential to substantially improve patient access to care, notably for individuals residing in remote areas or those facing mobility challenges. Furthermore, this model could alleviate the strain on oncology clinics, freeing up valuable resources for other critical services.
As healthcare systems increasingly prioritize patient autonomy and operational efficiency, home-based treatments for specific indications like LG-IR-NMIBC are likely to become more prevalent. This innovative delivery system, central to the observed efficacy and home administration, could pave the way for broader adoption of similar models in cancer care.
Future Directions
While the study’s results are encouraging, the researchers acknowledge certain limitations, including a small sample size and an open-label, single-arm design. Further research,including larger,controlled trials,is necessary to definitively confirm these findings and establish broader generalizability. Future investigations will also focus on the long-term impact of this approach on recurrence rates and disease progression, and also its cost-effectiveness.
Mitomycin for intravesical solution, when used with RTGel® technology, is approved for adults with recurrent LG-IR-NMIBC following prior ineffective bladder surgery. This advancement represents a significant step forward in making cancer treatment more accessible and patient-friendly.
REFERENCES:
- UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology. News release. UroGen. July 28, 2025. accessed July 28, 2025. https://tinyurl.com/4b45vzw2
- Morris D, Kramolowsky EV, Bivins VM, et al. Home instillation of UGN-102 for primary chemoablation of recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer: a single-arm,open-label,phase 3B trial.Uro Oncol*. 43, 3, 2025.DOI: 10.1016/J.Rolonc 201.2024.12.127